相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。A randomized controlled trial of quetiapine for psychosis in Parkinson’s disease
Paul Shotbolt
Neuropsychiatric Disease and Treatment (2010)
The dementia antipsychotic withdrawal trial (DART-AD): long-term follow-up of a randomised placebo-controlled trial
Clive Ballard et al.
LANCET NEUROLOGY (2009)
Hallucinations in Parkinson disease
Nico J. Diederich et al.
NATURE REVIEWS NEUROLOGY (2009)
Scales to assess psychosis in Parkinson's disease:: Critique and recommendations
Hubert H. Fernandez et al.
MOVEMENT DISORDERS (2008)
Role of 5HT2A and 5HT2C polymorphisms in behavioural and psychological symptoms of Alzheimer's disease
Antonia L. Pritchard et al.
NEUROBIOLOGY OF AGING (2008)
A 5-HT2A receptor inverse agonist, ACP-103, reduces tremor in a rat model and levodopa-induced dyskinesias in a monkey model
Kimberly E. Vanover et al.
PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR (2008)
Diagnostic criteria for psychosis in Parkinson's disease: Report of an NINDS, NIMH work group
Bernard Ravina et al.
MOVEMENT DISORDERS (2007)
The management of psychosis in movement disorder patients
Kelvin L. Chou et al.
EXPERT OPINION ON PHARMACOTHERAPY (2007)
Effect of quetiapine a double-blind in psychotic Parkinson's disease patients: Labeled study of 3 months' duration
Jose M. Rabey et al.
MOVEMENT DISORDERS (2007)
Treating dopamimetic psychosis in Parkinson's disease:: Structured review and meta-analysis
Helge Frieling et al.
EUROPEAN NEUROPSYCHOPHARMACOLOGY (2007)
Movement disorder society-sponsored revision of the unified Parkinson's disease rating scale (MDS-UPDRS): Process, format, and clinimetric testing plan
Christopher G. Goetz et al.
MOVEMENT DISORDERS (2007)
Rater-blinded, prospective comparison: Quetiapine versus clozapine for Parkinson's disease psychosis
Doron Merims et al.
CLINICAL NEUROPHARMACOLOGY (2006)
Occupancy of striatal and extrastriatal dopamine D2 receptors by clozapine and quetiapine
Robert M. Kessler et al.
NEUROPSYCHOPHARMACOLOGY (2006)
Pharmacological and behavioral profile of N-(4-fluorophenylmethyl)-N-(1-methylpiperidin-4-yl)-N′-(4-(2-methylpropyloxy)phenylmethyl) carbamide (2R, 3R)-dihydroxybutanedioate (2:1) (ACP-103), a novel 5-hydroxytryptamine2A receptor inverse agonist
KE Vanover et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2006)
Practice Parameter: Evaluation and treatment of depression, psychosis, and dementia in Parkinson disease (an evidence-based review) Report of the Quality Standards Subcommittee of the American Academy of Neurology
JM Miyasaki et al.
NEUROLOGY (2006)
Risk of death in elderly users of conventional vs. atypical antipsychotic medications
PS Wang et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Double-blind, placebo-controlled, unforced titration parallel trial of quetiapine for dopaminergic-induced hallucinations in Parkinson's disease
WG Ondo et al.
MOVEMENT DISORDERS (2005)
Psychotic symptoms in Parkinson's disease
S Papapetropoulos et al.
JOURNAL OF NEUROLOGY (2005)
Insular cortex abnormalities in schizophrenia: Relationship to symptoms and typical neuroleptic exposure
M Pressler et al.
BIOLOGICAL PSYCHIATRY (2005)
Psychosis in Parkinson's disease
DP Wint et al.
JOURNAL OF GERIATRIC PSYCHIATRY AND NEUROLOGY (2004)
Movement disorder society task force report on the Hoehn and Yahr staging scale: Status and recommendations
CG Goetz et al.
MOVEMENT DISORDERS (2004)
Association of the serotonin transporter and receptor gene polymorphisms in neuropsychiatric symptoms in Alzheimer disease
F Assal et al.
ARCHIVES OF NEUROLOGY (2004)
Quetiapine and clozapine in parkinsonian patients with dopaminergic psychosis
L Morgante et al.
CLINICAL NEUROPHARMACOLOGY (2004)
Placebo-controlled evaluation of four novel compounds for the treatment of schizophrenia and Schizoaffective disorder
HY Meltzer et al.
AMERICAN JOURNAL OF PSYCHIATRY (2004)
5-HT2AT102C receptor polymorphism and neuropsychiatric symptoms in Alzheimer's disease
LCW Lam et al.
INTERNATIONAL JOURNAL OF GERIATRIC PSYCHIATRY (2004)
Morphometry of the superior temporal plane in schizophrenia: Relationship to clinical correlates
B Crespo-Facorro et al.
JOURNAL OF NEUROPSYCHIATRY AND CLINICAL NEUROSCIENCES (2004)
Long-term evaluation of the effect of quetiapine on hallucinations, delusions and motor function in advanced Parkinson disease
FA Mancini et al.
CLINICAL NEUROPHARMACOLOGY (2004)
Rationale for current therapies in Parkinson's disease
J Romrell et al.
EXPERT OPINION ON PHARMACOTHERAPY (2003)
Serotonin receptors : their key role in drugs to treat schizophrenia
HY Meltzer et al.
PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY (2003)
Longitudinal outcome of Parkinson's disease patients with psychosis
SA Factor et al.
NEUROLOGY (2003)
Treatment of psychosis in Parkinson's disease - Safety considerations
HH Fernandez et al.
DRUG SAFETY (2003)
The effect of quetiapine on psychosis and motor function in parkinsonian patients with and without dementia
S Reddy et al.
MOVEMENT DISORDERS (2002)
Localization of 5-HT2A receptors on dopamine cells in subnuclei of the midbrain A10 cell group
C Nocjar et al.
NEUROSCIENCE (2002)
Prospective longitudinal assessment of hallucinations in Parkinson's disease
CG Goetz et al.
NEUROLOGY (2001)
M100,907, a selective 5-HT2A antagonist, attenuates dopamine release in the rat medial prefrontal cortex
EA Pehek et al.
BRAIN RESEARCH (2001)
Olanzapine and clozapine - Comparative effects on motor function in hallucinating PD patients
CG Goetz et al.
NEUROLOGY (2000)
Hallucinations in Parkinson's disease -: Prevalence, phenomenology and risk factors
G Fénelon et al.
BRAIN (2000)
Activation of 5-HT2A/2C receptors within the nucleus accumbens increases local dopaminergic transmission
QS Yan
BRAIN RESEARCH BULLETIN (2000)
分享论文
